Brief: Vistagen Announces Topline And Post-HOC Data From Palisade-4 Phase 3 Public Speaking Challenge Trial Of Fasedienol For The Acute Treatment Of Social Anxiety Disorder
BRIEF-Vistagen Announces Topline And Post-HOC Data From Palisade-4 Phase 3 Public Speaking Challenge Trial Of Fasedienol For The Acute Treatment Of Social Anxiety Disorder June 30 (Reuters) - VistaGen Therapeutics Inc VTGN.O:
VISTAGEN ANNOUNCES TOPLINE AND POST-HOC DATA FROM PALISADE-4 PHASE 3 PUBLIC SPEAKING CHALLENGE TRIAL OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER
VISTAGEN THERAPEUTICS INC: FASEDIENOL DID NOT ACHIEVE STATISTICALLY SIGNIFICANT IMPROVEMENT ON PRIMARY AND SECONDARY ENDPOINTS
VISTAGEN THERAPEUTICS INC: FAVORABLE SAFETY AND TOLERABILITY DATA WERE CONSISTENT WITH PREVIOUS CLINICAL TRIALS
VISTAGEN THERAPEUTICS - PLANS TO MEET WITH FDA ON REGISTRATION PATHWAY FOR FASEDIENOL WITH FUTURE PHASE 3 TRIAL
VISTAGEN THERAPEUTICS - POST-HOC ANALYSIS SHOWS NOMINAL STATISTICAL SIGNIFICANCE FOR FASEDIENOL IN VERY SEVERE SOCIAL ANXIETY SUBGROUP
Source text: ID:nBw5KCXPxa
Further company coverage: VTGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors